Acelyrin, Inc. (NASDAQ:SLRN) Investor Alert: Lawsuit Alleges False and Misleading Statements

A lawsuit was filed on behalf of investors in Acelyrin, Inc. (NASDAQ:SLRN) shares over alleged securities laws violations.


San Diego, CA -- (SBWire) -- 12/08/2023 --An investor, who purchased shares of Acelyrin, Inc. (NASDAQ: SLRN), filed a lawsuit over alleged violations of Federal Securities Laws by Acelyrin, Inc..

Investors who purchased shares of Acelyrin, Inc. (NASDAQ: SLRN) have certain options and for certain investors are short and strict deadlines running. Deadline: January 16, 2024. NASDAQ: SLRN investors should contact the Shareholders Foundation at or call +1(858) 779 - 1554.

Agoura Hills, CA based Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

On or around May 5, 2023, Acelyrin, Inc conducted its initial public offering ("IPO"), selling 30 million shares of common stock priced at $18.00 per share.

Then, on September 11, 2023, after the markets closed, Acelyrin, Inc announced disappointing top-line results from Part B of the Phase 2b/3 trial evaluating izokibep, the Company's lead drug candidate, for the treatment of moderate-to-severe hidradenitis suppurativa. Specifically, izokibep failed to show statistically significant reduction in abscesses and inflammatory nodules in patients as compared to placebo.

The plaintiff claims that between May 4, 2023 and September 11, 2023, the defendants made false and/or misleading statements and/or failed to disclose that izokibep was less effective in treating HS than Defendants had led investors to believe, that accordingly, Acelyrin overstated izokibep's clinical and/or commercial prospects, that as a result, Acelyrin also overstated the Company's business prospects post-IPO, and thatas a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Acelyrin, Inc. (NASDAQ: SLRN) have certain options and should contact the Shareholders Foundation.

Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739

About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

Media Relations Contact

Michael Daniels
Shareholders Foundation, Inc.

View this press release online at: